What Is It?
Not a SARM at all — a PPAR-delta receptor agonist (metabolic modulator). Developed by GlaxoSmithKline and terminated in 2007 due to cancer in every animal species tested.
How Does It Work?
MK-677 wasn't really a peptide. YK-11 wasn't really a SARM. GW-501516 isn't even close. It activates PPAR-delta, recruits PGC-1-alpha, and increases fatty acid oxidation. Shifts cells from burning glucose to burning fat.
Primary Benefits (research suggests)
- Improved HDL cholesterol and lowered VLDL in early studies
- Marketed by gray-market vendors as an "exercise mimetic"
Run the Numbers
Calculate your GW-501516 dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- Three layers of cancer evidence — (1) GSK's 2-year animal studies showed rapid cancer in rats AND mice, (2) Australia classified it Schedule 9 — same as heroin, (3) 2022 Nature Communications paper demonstrated PPAR-delta acceleration of KRAS pancreatic cancer.
- WADA banned.
- Still sold gray-market as supplements despite lethal animal data.
- For research purposes only — included as a critical evaluation case study.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track GW-501516 in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →